Prostate Cancer Clinical Trial
S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy
Summary
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antiandrogen drugs, such as abiraterone acetate, may lessen the amount of androgens made by the body. It may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
PURPOSE: This phase II trial is studying the side effects and how well abiraterone acetate works in treating patients with prostate cancer who have undergone initial hormone therapy.
Full Description
OBJECTIVES:
Primary
To assess the rate of achieving a prostate-specific antigen (PSA) of ≤ 0.2 ng/mL with abiraterone acetate therapy in men with metastatic prostate cancer with a sub-optimal response to androgen-deprivation therapy (ADT).
Secondary
To assess the overall survival and objective progression-free survival of this group of patients.
To assess PSA partial response.
To evaluate the qualitative and quantitative toxicity of abiraterone acetate.
OUTLINE: This is a multicenter study.
Patients receive abiraterone acetate orally daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Patients receive androgen blockade with GNRH agonist (goserelin acetate or leuprolide acetate) or a GNRH antagonist (degarelix) per the treating physician and this will be given continuously until evidence of disease progression. Bilateral surgical orchiectomy is also acceptable.
After completion of study therapy, patients are followed up every 3 months for 1 year and then every 6 months for up to 3 years.
Eligibility Criteria
DISEASE CHARACTERISTICS:
Histologically or cytologically proven diagnosis of adenocarcinoma of the prostate
Metastatic (M1) disease as evidenced by soft tissue and/or bony metastases at the time of initiation of androgen-deprivation therapy (ADT)
Must have at least one of the following:
Visceral disease (liver, lung, other viscera)
Bone metastases to sites in either the axial (spine, pelvis, ribs, or skull) and/or the appendicular (clavicle, humerus, or femur) skeleton
Distant lymph node disease (e.g., above the aortic bifurcation, etc.)
No small cell or neuroendocrine prostate cancer
Patients must be receiving ADT (e.g., gonadotropin-releasing hormone [GNRH] antagonist, with or without antiandrogen) prior to entering this study
Degarelix, a FDA-approved GNRH antagonist, is an acceptable form of ADT
Bilateral surgical orchiectomy is also acceptable
Suboptimal response to ADT induction as defined by the following criteria:
Declining PSA (current PSA is less than the PSA prior to starting ADT) that fails to reach 4 ng/mL or below despite continuous ADT
PSA of > 4 ng/mL must be observed between 6-12 months after the initiation of ADT
Documentation of failure to achieve this PSA of ≤ 4 ng/mL must be within 28 days of registration
The PSA must be obtained after any applicable antiandrogen washout period
If the PSA is declining or stable (defined as a PSA rise ≤ 0.1 ng/mL from nadir) and the patient is on an antiandrogen, they must remain on the antiandrogen
Patients with stable or declining PSA who have had previous antiandrogen exposure, but are not taking an antiandrogen at the time of registration, must wait at least 6 weeks from the last antiandrogen dose before registration and still demonstrate a stable or falling PSA which is > 4 ng/mL by month 12, in order to be eligible
If the PSA is rising and they are on an antiandrogen, formal antiandrogen washout must be performed (4 weeks for flutamide and 6 weeks for bicalutamide and nilutamide with no evidence of a falling PSA after washout)
No patients with radiographic progression when compared to available imaging studies performed prior to starting the GNRH agonist/antagonist therapy
Patients who have measurable disease must have radiographic assessment (at least an abdominal/pelvic CT scan) within 28 days prior to registration
Non-measurable disease must be assessed (i.e., bone scan) within 42 days prior to registration
No patients with a history of brain metastases or who currently have treated or untreated brain metastases
Patients with clinical evidence of brain metastases must have a brain CT scan or MRI negative for metastatic disease within 56 days prior to registration
PATIENT CHARACTERISTICS:
Zubrod performance status 0-2
ANC ≥ 1,500/μL
Platelet count ≥ 100,000/μL
Hemoglobin ≥ 10 g/dL
Serum creatinine ≤ 1.5 times the upper limit of normal (ULN) OR creatinine clearance ≥ 60 mL/min
Bilirubin ≤ 1.5 times ULN (unless documented Gilbert disease)
AST and ALT < 1.5 times ULN
Potassium ≥ 3.5 mmol/L
Patient must have a testosterone value of < 50 ng/dL obtained within 28 days prior to registration
Patients must have controlled blood pressure defined as systolic blood pressure < 160 mm Hg and diastolic blood pressure < 95 mm Hg
Patients with a history of hypertension are eligible provided blood pressure is controlled by anti-hypertensive treatment
Patients who have partners of child-bearing potential must be willing to use a method of birth control with adequate barrier protection during the study and for 1 week after the last study drug administration
Must be able to take oral medication without crushing, dissolving, or chewing tablets
Patients must not have a history of gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of abiraterone acetate
No other prior malignancy is allowed except for any of the following:
Adequately treated basal cell or squamous cell skin cancer
Adequately treated stage I or II cancer from which the patient is currently in complete remission
Any other cancer from which the patient has been disease-free for 5 years
No patients with active or symptomatic viral hepatitis or chronic liver disease
No moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment
No history of NYHA class III or IV heart failure
Patients must have LVEF ≥ 50%
No known allergies, hypersensitivity, or intolerance to abiraterone acetate, prednisone, or their excipients
PRIOR CONCURRENT THERAPY:
See Disease Characteristics
Patients with a history of prior neoadjuvant or adjuvant GNRH agonist/antagonist therapy (related to previous surgery or radiation) are eligible provided they finished this therapy at least two years prior to registration
Prior enrollment to SWOG-S0925 (either arm) is not exclusionary
At least 6 weeks since prior and no concurrent finasteride or dutasteride
At least 28 days since prior radiotherapy or surgery and recovered
At least 4 weeks since prior investigational products
At least 4 weeks since prior flutamide (6 weeks for bicalutamide and nilutamide) with no evidence of a falling PSA
No other concurrent oral antiandrogen
No prior or concurrent cytotoxic chemotherapy or radiopharmaceuticals for prostate cancer
No prior or concurrent ketoconazole for the treatment of prostate cancer
Not requiring more than 10 mg a day of prednisone for another medical indication
Not planning to receive any concurrent cytotoxic chemotherapy, immunotherapy, surgery, or radiotherapy during protocol treatment
No concurrent hormonal-acting agents, including diethylstilbestrol/DES, aldosterone, PC-SPES, or spironolactone
No concurrent antifungal medication (e.g., fluconazole or itraconazole)
No medications that alter cardiac conduction
No prior Provenge (sipuleucel-T)
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 178 Locations for this study
Jonesboro Arkansas, 72401, United States
Little Rock Arkansas, 72205, United States
Rogers Arkansas, 72758, United States
Antioch California, 94531, United States
Fremont California, 94538, United States
Fresno California, 93720, United States
Hayward California, 94545, United States
Marysville California, 95901, United States
Oakland California, 94611, United States
Redwood City California, 94063, United States
Richmond California, 94801, United States
Roseville California, 95661, United States
Sacramento California, 95817, United States
Sacramento California, 95823, United States
Sacramento California, 95825, United States
San Francisco California, 94115, United States
San Jose California, 95119, United States
San Rafael California, 94903, United States
Santa Clara California, 95051, United States
Santa Rosa California, 95403, United States
South San Francisco California, 94080, United States
Stockton California, 95210, United States
Truckee California, 96161, United States
Vacaville California, 95688, United States
Vallejo California, 94589, United States
Walnut Creek California, 94596, United States
Alamosa Colorado, 81101, United States
Aurora Colorado, 80045, United States
Colorado Springs Colorado, 80909, United States
Edwards Colorado, 81632, United States
Fort Collins Colorado, 80524, United States
Fort Collins Colorado, 80528, United States
Glenwood Springs Colorado, 81601, United States
Grand Junction Colorado, 81502, United States
Montrose Colorado, 81401, United States
Hartford Connecticut, 06105, United States
Orlando Florida, 32806, United States
'Aiea Hawaii, 96701, United States
'Aiea Hawaii, 96701, United States
Honolulu Hawaii, 96813, United States
Honolulu Hawaii, 96813, United States
Honolulu Hawaii, 96813, United States
Honolulu Hawaii, 96813, United States
Honolulu Hawaii, 96817, United States
Honolulu Hawaii, 96817, United States
Honolulu Hawaii, 96819, United States
Honolulu Hawaii, 96826, United States
Honolulu Hawaii, 96859, United States
Kailua Hawaii, 96734, United States
Lihue Hawaii, 96766, United States
Boise Idaho, 83706, United States
Boise Idaho, 83712, United States
Fruitland Idaho, 83619, United States
Lewiston Idaho, 83501, United States
Meridian Idaho, 83642, United States
Nampa Idaho, 83686, United States
Twin Falls Idaho, 83301, United States
Decatur Illinois, 62526, United States
Maywood Illinois, 60153, United States
Mount Vernon Illinois, 62864, United States
Normal Illinois, 61761, United States
Springfield Illinois, 62781, United States
Davenport Iowa, 52803, United States
Chanute Kansas, 66720, United States
Dodge City Kansas, 67801, United States
Fort Scott Kansas, 66701, United States
Great Bend Kansas, 67530, United States
Hays Kansas, 67601, United States
Hutchinson Kansas, 67502, United States
Independence Kansas, 67301, United States
Kansas City Kansas, 66112, United States
Kansas City Kansas, 66160, United States
Kingman Kansas, 67068, United States
Lawrence Kansas, 66044, United States
Liberal Kansas, 67901, United States
Newton Kansas, 67114, United States
Overland Park Kansas, 66210, United States
Parsons Kansas, 67357, United States
Pittsburg Kansas, 66762, United States
Pratt Kansas, 67124, United States
Salina Kansas, 67401, United States
Salina Kansas, 67401, United States
Shawnee Mission Kansas, 66204, United States
Topeka Kansas, 66606, United States
Topeka Kansas, 66606, United States
Wellington Kansas, 67152, United States
Wichita Kansas, 67208, United States
Wichita Kansas, 67208, United States
Wichita Kansas, 67214, United States
Wichita Kansas, 67214, United States
Wichita Kansas, 67214, United States
Winfield Kansas, 67156, United States
Lexington Kentucky, 40503, United States
Alexandria Louisiana, 71315, United States
Baton Rouge Louisiana, 70809, United States
Lafayette Louisiana, 70503, United States
Shreveport Louisiana, 71105, United States
Shreveport Louisiana, 71130, United States
Methuen Massachusetts, 01844, United States
Ann Arbor Michigan, 48106, United States
Ann Arbor Michigan, 48106, United States
Ann Arbor Michigan, 48109, United States
Battle Creek Michigan, 49017, United States
Bay City Michigan, 48708, United States
Big Rapids Michigan, 49307, United States
Dearborn Michigan, 48123, United States
Detroit Michigan, 48201, United States
Detroit Michigan, 48202, United States
Flint Michigan, 48503, United States
Flint Michigan, 48503, United States
Flint Michigan, 48532, United States
Flint Michigan, 48532, United States
Grand Rapids Michigan, 49503, United States
Grand Rapids Michigan, 49503, United States
Grand Rapids Michigan, 49503, United States
Grosse Pointe Woods Michigan, 48236, United States
Jackson Michigan, 49201, United States
Lansing Michigan, 48912, United States
Lapeer Michigan, 48446, United States
Livonia Michigan, 48154, United States
Mount Clemens Michigan, 48043, United States
Muskegon Michigan, 49444, United States
Petoskey Michigan, 49770, United States
Pontiac Michigan, 48341, United States
Port Huron Michigan, 48060, United States
Reed City Michigan, 49677, United States
Saginaw Michigan, 48601, United States
Traverse City Michigan, 49684, United States
Warren Michigan, 48093, United States
Jackson Mississippi, 39216, United States
Cape Girardeau Missouri, 63703, United States
Kansas City Missouri, 64108, United States
Kansas City Missouri, 64131, United States
Kansas City Missouri, 64154, United States
Lee's Summit Missouri, 64064, United States
Saint Louis Missouri, 63109, United States
Saint Louis Missouri, 63141, United States
Saint Louis Missouri, 63141, United States
Springfield Missouri, 65802, United States
Springfield Missouri, 65804, United States
Springfield Missouri, 65807, United States
Billings Montana, 59101, United States
Billings Montana, 59101, United States
Billings Montana, 59102, United States
Billings Montana, 59107, United States
Bozeman Montana, 59715, United States
Great Falls Montana, 59405, United States
Great Falls Montana, 59405, United States
Helena Montana, 59601, United States
Kalispell Montana, 59901, United States
Kalispell Montana, 59901, United States
Missoula Montana, 59807, United States
Missoula Montana, 59807, United States
Las Vegas Nevada, 89102, United States
Las Vegas Nevada, 89106, United States
Ridgewood New Jersey, 07450, United States
Albuquerque New Mexico, 87106, United States
Albuquerque New Mexico, 87131, United States
Santa Fe New Mexico, 87505, United States
Elmira New York, 14905, United States
Middletown New York, 10940, United States
Mineola New York, 11501, United States
New York New York, 10025, United States
Rochester New York, 14642, United States
Charlotte North Carolina, 28233, United States
Goldsboro North Carolina, 27534, United States
Statesville North Carolina, 28677, United States
Chillicothe Ohio, 45601, United States
Cincinnati Ohio, 45267, United States
Columbus Ohio, 43214, United States
Columbus Ohio, 43215, United States
Columbus Ohio, 43215, United States
Columbus Ohio, 43222, United States
Columbus Ohio, 43228, United States
Delaware Ohio, 43015, United States
Lancaster Ohio, 43130, United States
Marietta Ohio, 45750, United States
Mount Vernon Ohio, 43050, United States
Newark Ohio, 43055, United States
Portsmouth Ohio, 45662, United States
Springfield Ohio, 45505, United States
Westerville Ohio, 43081, United States
Zanesville Ohio, 43701, United States
Charleston South Carolina, 29425, United States
Florence South Carolina, 29501, United States
Kingsport Tennessee, 37662, United States
Knoxville Tennessee, 37916, United States
Houston Texas, 77030, United States
Houston Texas, 77030, United States
Houston Texas, 77030, United States
Houston Texas, 77030, United States
Lubbock Texas, 79415, United States
Temple Texas, 76508, United States
Salt Lake City Utah, 84112, United States
Centralia Washington, 98531, United States
Everett Washington, 98201, United States
Federal Way Washington, 98003, United States
Olympia Washington, 98506, United States
Puyallup Washington, 98372, United States
Tacoma Washington, 98405, United States
Tacoma Washington, 98405, United States
Tacoma Washington, 98405, United States
Tacoma Washington, 98405, United States
Tacoma Washington, 98499, United States
Casper Wyoming, 82609, United States
How clear is this clinincal trial information?